Evidence map›Paper›PMID 41756318›Full record

ArticleFrontiers in oncology2026

Preoperative prognostic model combining tumor burden score and tumor markers to predict long-term outcomes following hepatectomy for intrahepatic cholangiocarcinoma: a multi-institutional analysis.

Jun Fu, Tingfeng Huang, Qizhu Lin, Jingdong Li, Xinyu Bi, Jianming Wang, Fuyu Li, Jian Wang, Kui Wang, Jianying Lou and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jun Fu *Department of Hepatopancreatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Tingfeng Huang *Department of Hepatopancreatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Qizhu Lin *Department of Hepatopancreatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Jingdong LiDepartment of Hepatobiliary Surgery, The Affiliated Hospital of Chuanbei Medical University, Nanchong, Sichuan, China.
Xinyu BiDepartment of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Jianming WangDepartment of Hepatobiliary Surgery, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science Technology, Wuhan, Hubei, China.
Fuyu LiDepartment of Hepatobiliary Surgery, The West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Jian WangDepartment of Hepatobiliary Surgery, Renji Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China.
Kui WangDepartment of Hepatic Surgery (II), Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai, China.
Jianying LouDepartment of Hepatobiliary Surgery, The Second Hospital Affiliated to Zhejiang University, Hangzhou, Zhejiang, China.
Shi ChengDepartment of Hepatobiliary Surgery, Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.
Yongyi ZengDepartment of Hepatopancreatobiliary Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver malignancy with limited prognostic tools to guide treatment strategies. This study aimed to develop and validate a preoperative prognostic model combining tumor burden score (TBS), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9), termed the TCCA model, to predict outcomes in patients with ICC undergoing hepatectomy. Methods: Patients who underwent curative resection for ICC between 2014 and 2020 were retrospectively identified from a multi-institutional database. The impact of the TCCA model on overall survival (OS) and recurrence-free survival (RFS) was evaluated in training and validation cohorts. Predictive performance was evaluated using the area under the Receiver Operating Characteristic curve (AUC), the Akaike Information Criterion (AIC), and the C-index. Results: A total of 849 patients were included. Lower TCCA scores were associated with better median OS (score 0: 59.7 months; score 1: 31.3 months; score 2: 19.4 months; score 3: 11.5 months, respectively) and median RFS (28.8; 15.4; 9.7; 8.1 months, respectively). The TCCA model performed well in both the training cohort (AUC: 0.697 for OS and 0.649 for RFS) and the validation cohort (AUC: 0.672 for OS and 0.632 for RFS), outperforming the 8th edition TNM system and other models, with the highest C-index (0.734) and lowest AIC (3840). Subgroup analyses demonstrated that the TCCA model maintained good discriminative ability among patients with negative CEA or CA19-9 levels. Conclusion: The TCCA model accurately stratifies ICC patients for OS and RFS after resection. It provides a simple and practical tool for preoperative risk assessment, supporting individualized surgical decision-making and individualized patient counseling.

Indexed as

adjuvant chemotherapycarbohydrate antigen 19-9 (CA 19-9)carcinoembryonic antigen (CEA)preoperative risk modeltumor burden score (TBS)

Identifiers

PMID41756318
PMCPMC12932142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.